INmune Bio Inc (INMB) Expected to Post Earnings of -$0.19 Per Share

Brokerages forecast that INmune Bio Inc (NASDAQ:INMB) will post earnings per share of ($0.19) for the current quarter, according to Zacks. Zero analysts have issued estimates for INmune Bio’s earnings. The company is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that INmune Bio will report full-year earnings of ($0.76) per share for the current financial year. For the next year, analysts expect that the business will report earnings of ($0.75) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow INmune Bio.

Separately, Maxim Group started coverage on INmune Bio in a research report on Tuesday, March 19th. They set a “buy” rating and a $13.00 price target on the stock.

Shares of INMB stock traded up $0.07 during trading hours on Wednesday, reaching $10.82. 5,730 shares of the company’s stock were exchanged, compared to its average volume of 16,353. INmune Bio has a fifty-two week low of $7.00 and a fifty-two week high of $11.50.

In related news, major shareholder Linda F. Powers acquired 61,667 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were purchased at an average cost of $9.00 per share, with a total value of $555,003.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Raymond Joseph Tesi acquired 11,100 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were bought at an average cost of $9.90 per share, for a total transaction of $109,890.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 77,767 shares of company stock worth $709,893.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Featured Story: How do analysts define an oversold condition?

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with's FREE daily email newsletter.